Thus in this limited library of compounds previously reported to cause phospholipidosis, LPLA2 inhibition was observed for almost three-quarters of the drugs that would have been considered false-negatives by the Ploemen or modified Ploemen criteria. This evidence concerns the gene PLA2G15 and lysosomal storage disease.